Fingerprint
Dive into the research topics of 'Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors
Manisha H. Shah, Paul Lorigan, Mary E.R. O’Brien, Frank V. Fossella, Kathleen N. Moore, Shailender Bhatia, Maurice Kirby, Penella J. Woll
Research output: Contribution to journal › Article › peer-review
49
Scopus
citations